目的 分析艾地苯醌聯(lián)合倍他司汀治療腦梗死后認(rèn)知功能障礙的臨床療效。方法 選取2020年1月-2021年10月長(zhǎng)治醫(yī)學(xué)院附屬和平醫(yī)院98例腦梗死后認(rèn)知功能障礙患者,采用區(qū)組隨機(jī)分組法分為對(duì)照組(49例)和治療組(49例)。對(duì)照組口服鹽酸倍他司汀片,8 mg/次,3次/d。治療組在對(duì)照組基礎(chǔ)上口服艾地苯醌片,30 mg/次,3次/d。兩組患者均治療2個(gè)月。觀察兩組患者臨床療效,比較治療前后兩組患者血液流變學(xué)指標(biāo)血細(xì)胞比容(HCT)、纖維蛋白原(FIB)和血小板黏附率(PAR)水平,氧化應(yīng)激指標(biāo)超氧化物歧化酶(SOD)和丙二醛(MDA)水平,神經(jīng)功能指標(biāo)視錐蛋白樣蛋白-1(VILIP-1)、胰島素樣生長(zhǎng)因子-1(IGF-1)和腦源性神經(jīng)營(yíng)養(yǎng)因子(BDNF)水平。結(jié)果 治療后,治療組總有效率(95.92%)較對(duì)照組(79.59%)明顯升高(P<0.05)。治療1、2個(gè)月,兩組HCT、FIB、PAR、MDA、VILIP-1水平明顯低于治療前(P<0.05),且治療2個(gè)月時(shí)低于治療1個(gè)月(P<0.05);治療1、2個(gè)月,治療組這些指標(biāo)低于同期對(duì)照組(P<0.05);治療1、2個(gè)月,兩組簡(jiǎn)易智能精神狀態(tài)量表(MMSE)評(píng)分、SOD、IGF-1及BDNF水平高于治療前(P<0.05),且治療2個(gè)月高于治療1個(gè)月(P<0.05);治療1、2個(gè)月,治療組這些指標(biāo)高于同期對(duì)照組(P<0.05)。結(jié)論 艾地苯醌聯(lián)合倍他司汀用于腦梗死后認(rèn)知功能障礙可提高療效,加快恢復(fù)認(rèn)知功能,促進(jìn)神經(jīng)功能、血液流變學(xué)改善,抑制氧化應(yīng)激損傷,安全可靠。

Objective To analyze the effect of idebenone combined with betahistine in treatment of cognitive dysfunction after cerebral infarction. Methods Patients (98 cases) with cognitive dysfunction after cerebral infarction in Heping Hospital Affiliated to Changzhi Medical College from January 2020 to October 2021 were divided into control (49 cases) and treatment (49 cases) group according to block randomization. Patients in the control group were po administered with Betahistine Hydrochloride Tablets, 8 mg/time, three times daily. Patients in the treatment group po administered with Idebenone Tablets on the basis of the control group, 30 mg/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical evaluation was evaluated, and the levels of blood rheological indicators HCT, FIB and PAR, the oxidative stress indexes SOD and MDA levels, the levels of neurological function indicators VILIP-1, IGF-1 and BDNF in two groups before and after treatment were compared. Results After treatment, the total effective rate of the treatment group (95.92%) was significantly higher than 79.59% of the control group (P＜0.05). After 1 and 2 months of treatment, the levels of HCT, FIB, PAR, MDA and VILIP-1 in two groups were significantly lower than those before treatment (P＜0.05), the levels of 2 months after treatment was lower than that at 1 month (P＜0.05), and which in the treatment group was lower than that in the control group (P＜0.05). After treatment for 1 and 2 months, the MMSE scores, SOD, IGF-1 and BDNF in two groups were higher than those before treatment (P＜0.05), and which after the two-month treatment was higher than that after the first month (P＜0.05), and these indexes in the treatment group was higher than the control group (P＜0.05). Conclusion Idebenone combined with betastine in treatment of cognitive impairment after cerebral infarction can improve the therapeutic effect, accelerate the recovery of cognitive function, promote the improvement of neurological function and hemorheology, inhibit oxidative stress injury, and which is safe and reliable.

R971

山西省2020年研究生創(chuàng)新項(xiàng)目(2020SY447)